Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

BioPharma« Terug naar discussie overzicht

Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs

675 Posts
Pagina: «« 1 2 3 4 5 6 ... 34 »» | Laatste | Omlaag ↓
  1. [verwijderd] 7 juni 2021 08:48
    van het artikel dat Immutep op twitter plaatste:

    Positive overall response rates
    ”In second-line head and neck cancer, with the best available standard of care, the median overall survival rate is only six to nine months. It’s a terrible, extremely aggressive disease and with Keytruda alone you expect a response rate (where the tumour shrinks) of around 15 per cent, but we’re seeing a rate of about 30 per cent.”

    While the overall response rates were positive, especially given the tough-to-treat nature of the cancers, Firetrail Investments equity analyst Eleanor Swanson was most bullish about the fact that five patients in the head and neck cancer trial had a complete response, meaning the efti plus Keytruda combination destroyed the cancer.

    www.afr.com/technology/investors-buoy...
  2. Kijkboek 8 juni 2021 03:05
    Immutep Reveals a New anti-LAG-3 Research Program
    SYDNEY, AUSTRALIA – 8 June 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline.

    www.immutep.com/files/content/investo...
  3. Maisha marefu 8 juni 2021 07:52
    quote:

    Kijkboek schreef op 8 juni 2021 03:05:

    Immutep Reveals a New anti-LAG-3 Research Program
    SYDNEY, AUSTRALIA – 8 June 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline.

    www.immutep.com/files/content/investo...
    Prachtige berichtgeving van dit bedrijf. Ik krijg ook de mails van Immutep telkens netjes binnen! Schitterend aandeel en schitterend bedrijf!
  4. [verwijderd] 8 juni 2021 10:09
    quote:

    Kijkboek schreef op 8 juni 2021 03:05:

    Immutep Reveals a New anti-LAG-3 Research Program
    SYDNEY, AUSTRALIA – 8 June 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline.

    www.immutep.com/files/content/investo...
    “We are delighted to collaborate with Immutep on this important project to develop a small molecule antiLAG-3 treatment for cancer patients that could offer the convenience of a tablet or capsule, at a fraction of
    the cost of existing anti-LAG-3 candidates,” said Professor Andrew Godkin of Cardiff University.

    dat zou toch geweldig zijn :-)
  5. Kijkboek 11 juni 2021 02:31
    Fyi, had gevraagd wat op de planning stond voor dit event.

    Dear XX,

    Thanks for your enquiry about Immutep’s participation in the BIO International Convention - Bio Digital 2021.

    CEO Marc Voigt and other members of the team will be there to conduct individual meetings but there is no planned presentation.

    Please let us know if you have any further questions.

    Regards,
    Matt
675 Posts
Pagina: «« 1 2 3 4 5 6 ... 34 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.